DE1792207C3 - Pulverpräparat zur Inhalation - Google Patents

Pulverpräparat zur Inhalation

Info

Publication number
DE1792207C3
DE1792207C3 DE1792207A DE1792207A DE1792207C3 DE 1792207 C3 DE1792207 C3 DE 1792207C3 DE 1792207 A DE1792207 A DE 1792207A DE 1792207 A DE1792207 A DE 1792207A DE 1792207 C3 DE1792207 C3 DE 1792207C3
Authority
DE
Germany
Prior art keywords
weight
lactose
particle size
effective
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE1792207A
Other languages
German (de)
English (en)
Other versions
DE1792207A1 (de
DE1792207B2 (de
Inventor
Stephen Raymond East Leake Loughborough Gunning
Philip Saxton Springfield Kegworth Hartley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Ltd
Original Assignee
Fisons Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Ltd filed Critical Fisons Ltd
Publication of DE1792207A1 publication Critical patent/DE1792207A1/de
Publication of DE1792207B2 publication Critical patent/DE1792207B2/de
Application granted granted Critical
Publication of DE1792207C3 publication Critical patent/DE1792207C3/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fastening Of Light Sources Or Lamp Holders (AREA)
DE1792207A 1967-08-08 1968-08-03 Pulverpräparat zur Inhalation Expired DE1792207C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB36270/67A GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
DE1792207A1 DE1792207A1 (de) 1971-11-04
DE1792207B2 DE1792207B2 (de) 1977-10-13
DE1792207C3 true DE1792207C3 (de) 1978-06-29

Family

ID=10386572

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1792207A Expired DE1792207C3 (de) 1967-08-08 1968-08-03 Pulverpräparat zur Inhalation
DE19681792799 Ceased DE1792799A1 (de) 1967-08-08 1968-08-03 Pharmazeutische praeparate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE19681792799 Ceased DE1792799A1 (de) 1967-08-08 1968-08-03 Pharmazeutische praeparate

Country Status (14)

Country Link
US (1) US3634582A (enExample)
JP (1) JPS5643448B1 (enExample)
BE (1) BE718846A (enExample)
CA (1) CA946280A (enExample)
DE (2) DE1792207C3 (enExample)
DK (1) DK123276B (enExample)
FI (1) FI48973C (enExample)
FR (2) FR8142M (enExample)
GB (1) GB1242211A (enExample)
IE (1) IE32343B1 (enExample)
MY (2) MY7400330A (enExample)
NL (1) NL161984C (enExample)
NO (1) NO128307B (enExample)
SE (1) SE372420B (enExample)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381872A (en) * 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
BE787100A (fr) * 1971-08-06 1973-02-02 Beecham Group Ltd Composition pour le traitement de l'asthme
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
DE2332663C2 (de) * 1973-06-23 1986-07-31 Schering AG, 1000 Berlin und 4709 Bergkamen Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie
DE2535258C2 (de) * 1974-08-10 1993-06-03 Fisons Plc, Ipswich, Suffolk Inhalierbares Medikament in Pelletform
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
IL51314A (en) * 1976-01-30 1980-03-31 Fisons Ltd Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
GB2077100B (en) * 1980-04-30 1985-04-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
BE891013A (fr) * 1980-11-05 1982-05-05 Fisons Ltd Compositions pharmaceutique
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
DE3872635T2 (de) * 1987-04-09 1992-12-17 Fisons Plc Pentamidin enthaltende pharmazeutische zusammensetzungen.
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
WO1993025193A1 (fr) * 1992-06-12 1993-12-23 Teijin Limited Preparation pharmaceutique destinee a etre administree par les voies respiratoires
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
ES2166786T3 (es) * 1993-10-01 2002-05-01 Astrazeneca Ab Procedimiento i.
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
NL9301851A (nl) * 1993-10-26 1995-05-16 Cordis Europ Cryo-ablatie catheter.
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
JP4155594B2 (ja) 1994-12-22 2008-09-24 アストラゼネカ・アクチエボラーグ エアゾール製剤
EP1283035A3 (en) 1994-12-22 2003-03-19 AstraZeneca AB Therapeutic preparation for inhalation containing parathyroid hormone
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
BR9809499A (pt) * 1997-05-27 2000-06-20 Direct Haler A S Inalador para medicamentos em pó
EP1119349B1 (en) 1998-08-18 2008-07-02 The Regents Of The University Of California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
PL352615A1 (en) 1999-06-05 2003-08-25 Innovata Biomed Ltd Delivery system
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AP1712A (en) * 2000-10-12 2007-01-24 Boehringer Ingelheim Pharma Novel tiotropium-containing inhalation powder
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
DE10141377A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
EP1487417A4 (en) * 2001-09-17 2010-03-17 Glaxo Group Ltd DRY POWDER DRUG FORMULATIONS
BR0214280A (pt) * 2001-11-19 2005-01-11 Becton Dickinson Co Composição farmacêuticas em forma particulada
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
JP2006516531A (ja) * 2002-08-21 2006-07-06 ノートン　ヘルスケアー　リミテッド 吸入組成物
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
DE10317461A1 (de) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
US20050042179A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
US20050042178A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
US20050043247A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
PL1699434T3 (pl) 2003-09-02 2011-09-30 Norton Healthcare Ltd Sposób wytwarzania leku
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005102429A1 (en) 2004-04-21 2005-11-03 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004048389A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
DE102004048390A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff
BRPI0606364A2 (pt) * 2005-02-10 2010-03-23 Glaxo Group Ltd processo para formar lactose adequada para uso em uma formulaÇço farmacÊutica
WO2010010538A2 (en) 2008-07-24 2010-01-28 L'air Liquide-Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Heteroleptic cyclopentadienyl transition metal precursors for deposition of transition metal-containing films
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
PT106094A (pt) 2012-01-13 2013-07-15 Hovione Farmaciencia S A Administração por inalação de formulações com dose elevada
US20150165038A1 (en) * 2012-02-10 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and sorbitol
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN106061482A (zh) 2013-10-08 2016-10-26 拉姆医疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
WO2019003118A1 (en) 2017-06-28 2019-01-03 Philip Morris Products S.A. CONTAINER WITH PARTICLES FOR USE WITH INHALER
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
ES2953293T3 (es) 2018-08-07 2023-11-10 Norton Waterford Ltd Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
EP4203945A1 (en) 2020-08-28 2023-07-05 Universität Linz Use of leoligin in the prevention of tissue damage
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
WO2026002967A1 (en) 2024-06-24 2026-01-02 Universität Linz Leoligin and derivatives thereof as calcium channel blockers for the prevention and/or treatment of related diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1489749A (fr) 1965-03-25 1967-07-28 Fisons Pharmaceuticals Ltd Procédé de préparation de composés bis-chromonylés et leurs dérivés

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792207U (de) 1959-04-14 1959-07-16 Esslinger Sack Und Planenfabri Transportables gartenschwimm- oder -planschbecken mit aus kunststoff-folie bestehenden waenden.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1489749A (fr) 1965-03-25 1967-07-28 Fisons Pharmaceuticals Ltd Procédé de préparation de composés bis-chromonylés et leurs dérivés

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hager: Handbuch der pharmazeutischen Praxis, 2. Erg.-Bd., Teil II, 1958, S. 1222-1225

Also Published As

Publication number Publication date
NL161984C (nl) 1980-04-15
NO128307B (enExample) 1973-10-29
BE718846A (enExample) 1969-01-31
GB1242211A (en) 1971-08-11
NL161984B (nl) 1979-11-15
DE1792799A1 (de) 1977-08-11
CA946280A (en) 1974-04-30
US3634582A (en) 1972-01-11
FR1605538A (enExample) 1979-02-23
NL6811060A (enExample) 1969-02-11
DK123276B (da) 1972-06-05
FI48973B (enExample) 1974-12-02
MY7400329A (en) 1974-12-31
FR8142M (enExample) 1970-08-17
DE1792207A1 (de) 1971-11-04
MY7400330A (en) 1974-12-31
SE372420B (enExample) 1974-12-23
DE1792207B2 (de) 1977-10-13
JPS5643448B1 (enExample) 1981-10-13
FI48973C (fi) 1975-03-10
IE32343B1 (en) 1973-06-27
IE32343L (en) 1969-02-08

Similar Documents

Publication Publication Date Title
DE1792207B2 (de) Pulverpraeparat zur inhalation
DE2229981C3 (de) Pharmazeutische Pulverpräparate
DE69631119T2 (de) Pulver zur verwendung in trockenpulverinhalatoren
DE69631159T2 (de) Pulver und deren verwendung in trockenpulverinhalatoren
DE69426459T2 (de) Verbesserung in verbindung mit trägerpartikeln zur verwendung in trockenpulverinhalatoren
DE69429357T2 (de) Verfahren i
DE60123031T2 (de) Pharmazeutische formulierungen für trockenpulverinhalatoren in form von hartpellets
DE69828886T3 (de) Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, verfahren zur herstellung der formulierung sowie anwendung derselben
US3957965A (en) Sodium chromoglycate inhalation medicament
DE69936268T2 (de) Verbesserte pulverförmige pharmazeutische Zusammensetzungen zur Verwendung in Trockenpulverinhalatoren
DE69100792T2 (de) Aerosolträger.
DE60225242T2 (de) Verfahren zur herstellung von nanopartikeln
DE69907951T2 (de) Verbesserungen in bezug auf pulver
DE4140689B4 (de) Inhalationspulver und Verfahren zu ihrer Herstellung
DE69812169T2 (de) Mikropartikel und ihre therapeutische oder diagnostische verwendung
EP0771189B1 (de) Formulierung zur inhalativen applikation
DE60104399T2 (de) Pulverformulierung zur inhalation
DE60128902T2 (de) Formulierungen zur verwendung in inhalationsvorrichtungen
DE60003162T2 (de) Modifizierte trägerpartikel zur verwendung in trockenpulverinhalatoren
DE69839275T2 (de) Neue formulierung zur inhalation mit einer bulkdichte zwischen 0,28 und 0,38 g/ml enthaltend budensonide
DE69306379T2 (de) Inhalierbare arzneimittel
DE60029457T2 (de) Verfahren zur herstellung von feinkörnigen medizinischen substanzen
DE2239091A1 (de) Pharmazeutische pulverzusammensetzung
DE69821119T2 (de) Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, mit formoterol
DE4400295B4 (de) Verfahren zum Herstellen eines sphärischen Granulums

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
8327 Change in the person/name/address of the patent owner

Owner name: FISONS PLC, IPSWICH, GB

8328 Change in the person/name/address of the agent

Free format text: DANNENBERG, G., DIPL.-ING., 6000 FRANKFURT SCHMIED-KOWARZIK, V., DR. WEINHOLD, P., DIPL.-CHEM. DR.,PAT.-ANW., 8000 MUENCHEN